Lang FF - Search Results

1

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Jiang H, et al. Among authors: lang ff. PLoS One. 2014 May 14;9(5):e97407. doi: 10.1371/journal.pone.0097407. eCollection 2014. PLoS One. 2014. PMID: 24827739 Free PMC article.

2

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA. Lang FF, et al. Neuro Oncol. 2002 Oct;4(4):268-77. doi: 10.1093/neuonc/4.4.268. Neuro Oncol. 2002. PMID: 12356357 Free PMC article.

3

Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.

Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Fueyo J, et al. Among authors: lang ff. J Natl Cancer Inst. 2003 May 7;95(9):652-60. doi: 10.1093/jnci/95.9.652. J Natl Cancer Inst. 2003. PMID: 12734316

4

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. Lang FF, et al. J Clin Oncol. 2003 Jul 1;21(13):2508-18. doi: 10.1200/JCO.2003.21.13.2508. J Clin Oncol. 2003. PMID: 12839017 Clinical Trial.

5

Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.

Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ. Cerrato JA, et al. Among authors: lang ff. Int J Oncol. 2004 Feb;24(2):409-17. Int J Oncol. 2004. PMID: 14719118

6

A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.

Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. Gomez-Manzano C, et al. Among authors: lang ff. Oncogene. 2004 Mar 11;23(10):1821-8. doi: 10.1038/sj.onc.1207321. Oncogene. 2004. PMID: 15014451

7

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.

Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Conrad C, et al. Among authors: lang ff. Cancer Gene Ther. 2005 Mar;12(3):284-94. doi: 10.1038/sj.cgt.7700750. Cancer Gene Ther. 2005. PMID: 15650766

8

Mechanisms of action of rapamycin in gliomas.

Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Heimberger AB, et al. Among authors: lang ff. Neuro Oncol. 2005 Jan;7(1):1-11. doi: 10.1215/S1152851704000420. Neuro Oncol. 2005. PMID: 15701277 Free PMC article.

9

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.

Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Nakamizo A, et al. Among authors: lang ff. Cancer Res. 2005 Apr 15;65(8):3307-18. doi: 10.1158/0008-5472.CAN-04-1874. Cancer Res. 2005. PMID: 15833864

10

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.

Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Gomez-Manzano C, et al. Among authors: lang ff. Clin Cancer Res. 2006 Jan 15;12(2):556-62. doi: 10.1158/1078-0432.CCR-05-1892. Clin Cancer Res. 2006. PMID: 16428500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

258 results

Search Page